Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 12/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17157090 | 1.00 | TMEM97 (0.48) | TMEM97SIGMAR1PDE4BCTSLMEN1 | |
| SCHEMBL11981643 | 0.88 | ALDH1A1 (0.49) | TMEM97SIGMAR1CTSLMEN1KMT2A | |
| SCHEMBL7884848 | 0.82 | KMT2A (0.48) | MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL16075642 | 0.82 | NPFFR1 (0.48) | SIGMAR1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL24403426 | 0.82 | NPFFR1 (0.48) | SIGMAR1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL15670663 | 0.81 | ALDH1A1 (0.46) | PDE4BCTSLKMT2ANPSR1 | |
| SCHEMBL19635979 | 0.81 | SYK (0.39) | TMEM97SIGMAR1PDE4BCTSLKMT2A | |
| SCHEMBL15670661 | 0.81 | ALDH1A1 (0.46) | PDE4BCTSLKMT2ANPSR1 | |
| SCHEMBL30793400 | 0.80 | TMEM97 (0.54) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL30793327 | 0.80 | TMEM97 (0.54) | TMEM97SIGMAR1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190202798-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-10266513-B2 | Bruton's tyrosine kinase inhibitors | PFIZER INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170283393-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2914586-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | PFIZER (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20150376193-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| US-9156847-B2 | Processes and intermediates for preparing a medicament | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-13 | — | — | US | disclosed |
| US-20140275126-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266513-B2 | Bruton's tyrosine kinase inhibitors | BTK, LCK, LYN | TMEM97 3965/4885SIGMAR1 4583/4885PDE4B 1952/4885 |
| US-20150376193-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | BTK, SYK, JAK2 | TMEM97 2630/4885SIGMAR1 2212/4885PDE4B 1362/4885 |
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | TMEM97 4027/4885SIGMAR1 4599/4885PDE4B 2197/4885 |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | BTK, LCK, LYN | TMEM97 3883/4885SIGMAR1 4508/4885PDE4B 2245/4885 |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | TMEM97 3883/4885SIGMAR1 4508/4885PDE4B 2245/4885 |
| US-20140275126-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | BTK, SYK, JAK2 | TMEM97 2630/4885SIGMAR1 2212/4885PDE4B 1362/4885 |
| US-20170283393-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | TMEM97 3965/4885SIGMAR1 4583/4885PDE4B 1952/4885 |
| US-20190202798-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, SYK | TMEM97 3997/4885SIGMAR1 4589/4885PDE4B 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.